A Korean single-center, real-world, retrospective study of first-line weekly paclitaxel in patients with metastatic angiosarcoma
Conclusions
In this retrospective study, first-line chemotherapy with weekly paclitaxel demonstrated clinically relevant efficacy and tolerability in unselected Korean patients with metastatic angiosarcoma. It is encouraging that response rate and PFS for Korean patients were similar to those reported in Western reports.
Source: Clinical Sarcoma Research - Category: Cancer & Oncology Source Type: research
More News: Anemia | Angiosarcoma | Cancer | Cancer & Oncology | Cardiology | Chemotherapy | Clinical Trials | Heart | Hematology | Neurology | Peripheral Neuropathy | Sarcomas | Soft Tissue Sarcoma | Study | Toxicology